Ticaros: Funding, Investors & Team (Sep 2026)
Ticaros is a biotech company that develops immune anti-cancer drugs.
Ticaros has raised $14.0M across 1 funding round on record, the most recent a Series D of $14.0M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ticaros Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Ticaros Funding Rounds
Ticaros Founders and Leadership Team
Contact details for the Ticaros team: 1 has a LinkedIn profile.
Start 14-day free trial →Ticaros Funding Compared to Other Biotechnology Startups
Ticaros' latest round of $14.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Biotechnology Startups Like Ticaros
Companies Similar to Ticaros
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Ticaros Funding FAQs
What does Ticaros do?
Ticaros is a biotech company that develops immune anti-cancer drugs.
How much funding has Ticaros raised?
Ticaros has raised $14.0M across 1 round on record. The most recent is a Series D of $14.0M announced in Mar 2026.
When did Ticaros last raise funding?
Ticaros' most recent funding round on record is a Series D of $14.0M, announced in Mar 2026.
Who founded Ticaros?
FundedIQ lists Daniel Suhong Kim (Founder) at Ticaros.
How many employees does Ticaros have?
Ticaros is in the 11-50 employee band.
How does Ticaros' funding compare to other Biotechnology startups?
Ticaros' latest round of $14.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Ticaros Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ticaros is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.